Zobrazeno 1 - 10
of 15
pro vyhledávání: '"Charles F, Eisenbeis"'
Autor:
Sharon Wilks, Scot Sedlacek, Praveen K. Reddy, Jagathi D. Challagalla, Mary Ann K Allison, Joyce O'Shaughnessy, Charles F. Eisenbeis, Carlos A. Taboada, Yunfei Wang, Marcus A. Neubauer, Nicholas Koutrelakos, Sasha Vukelja, Cynthia Osborne, Lina Asmar, Frankie A. Holmes
Publikováno v:
Clinical Breast Cancer. 18:e89-e95
Background Hormonal therapies and single-agent sequential chemotherapeutic regimens are the standards of care for HER2 − metastatic breast cancer (MBC). However, treating patients with hormone-refractory and triple negative (TN) MBC remains challen
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::295433f92c1f176d5eb81f4fbd64e606
https://doi.org/10.1016/j.clbc.2017.07.002
https://doi.org/10.1016/j.clbc.2017.07.002
Autor:
Amy Banks, Pablo Garcia, Pierluigi Porcu, Lawrence D. Piro, Michael A. Caligiuri, Amy K. Ferketich, John P. Leonard, Don M. Benson, Lei Chen, Khuda D. Khan, Sandra Milan, Glenn C. Michelson, Christos Emmanouilides, John C. Byrd, Deborah Hurst, Charles F. Eisenbeis
Publikováno v:
Clinical Cancer Research. 12:7046-7053
Purpose: The incidence of non-Hodgkin's lymphoma (NHL), the fifth most common malignancy in the United States, has increased over 70% in the last 30 years. Fifty percent to 75% of patients with low-grade or follicular NHL respond to rituximab therapy
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::87c53a87335233ce96eb3184654124da
https://doi.org/10.1158/1078-0432.ccr-06-1571
https://doi.org/10.1158/1078-0432.ccr-06-1571
Autor:
Charles F. Eisenbeis, Donn C. Young, Amy Banks, John C. Byrd, T. S. Lin, Andrew P. Mone, Carolyn Cheney, Sara K. Guster, Susheela Tridandapani, Najma Mehter
Publikováno v:
Leukemia. 20:272-279
Alemtuzumab is a humanized IgG1 kappa antibody directed against CD52, a glycosyl-phosphatidylinositol linked cell-membrane protein of unknown function. Herein, we demonstrate that alemtuzumab promotes rapid death of chronic lymphocytic leukemia (CLL)
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::42de0171dcd5021e9a064d46615df912
https://doi.org/10.1038/sj.leu.2404014
https://doi.org/10.1038/sj.leu.2404014
Autor:
Ronald P. Pelletier, Charles F. Eisenbeis, Sameek Roychowdhury, Michael A. Caligiuri, Amy K. Ferketich, Anne M. VanBuskirk, Julie Dierksheide, Robert A. Baiocchi
Publikováno v:
Blood. 105:1558-1565
Posttransplantation lymphoproliferative disorder (PTLD) is a devastating post-transplantation complication often associated with Epstein-Barr virus (EBV). Although the type and length of immunosuppression are risk factors, a patient's inherent immune
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::437f294a0002ac31b6777f97b5d948fd
https://doi.org/10.1182/blood-2003-07-2476
https://doi.org/10.1182/blood-2003-07-2476
Autor:
William L. Marsh, Charles F. Eisenbeis, Robert A. Baiocchi, Gerard J. Nuovo, Sameek Roychowdhury, Elizabeth A. Davies, Srinivas Vourganti, Ronald P. Pelletier, Ronald M. Ferguson, Mitchell L. Henry, Michael A. Caligiuri, Amy K. Ferketich, Pierluigi Porcu
Publikováno v:
Blood. 100:2341-2348
Posttransplantation lymphoproliferative disorder (PTLD) is a life-threatening Epstein-Barr virus (EBV)–associated B-cell malignancy occurring in 1% to 2% of renal transplantation patients. Host- and PTLD-related factors determining the likelihood o
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d3902b33625cb89229b096b37288ab99
https://doi.org/10.1182/blood-2002-01-0210
https://doi.org/10.1182/blood-2002-01-0210
Publikováno v:
Genes & Development. 9:1377-1387
The immunoglobulin light-chain gene enhancers E kappa 3', E lambda 2-4, and E lambda 3-1 contain a conserved cell type-specific composite element essential for their activities. This element binds a B cell-specific heterodimeric protein complex that
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9ac9511037ac822c8d234a3c47c932c4
https://doi.org/10.1101/gad.9.11.1377
https://doi.org/10.1101/gad.9.11.1377
Autor:
Michael Walker, Padma Nadella, Donn C. Young, Poongothai Sundaram, Mirela Anghelina, Gregory B. Lesinski, William E. Carson, Mario Sznol, Robin Parihar, Charles F. Eisenbeis, Jing Liu, Daniel Valentino
Publikováno v:
Journal of clinical oncology : official journal of the American Society of Clinical Oncology. 23(34)
PurposeTo evaluate the safety of sequentially administered recombinant (r) human (h) interleukin-12 (IL-12) and interferon alfa-2b (IFN-α-2b) in patients with advanced cancer and to determine the effects of endogenously produced IFN-γ on Janus kina
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::fee73c8a8fc9e7b81c391ee4ebe67fee
https://pubmed.ncbi.nlm.nih.gov/16314644
https://pubmed.ncbi.nlm.nih.gov/16314644
Autor:
Shannon Puhalla, Robert A. Baiocchi, John C. Byrd, Andrew P. Mone, Tamara Vukosavljevic, Amy Banks, Charles F. Eisenbeis, Susan P. Whitman, Julio Cruz, Michael A. Caligiuri, Pierluigi Porcu
Publikováno v:
Blood. 106(10)
Adult T-cell leukemia (ATL) is a highly chemoresistant and usually fatal T-cell malignancy due to the human T-cell lymphotropic virus-1 (HTLV-1). After chemotherapy failure, antiretrovirals and interferon-α (IFN-α) produce brief responses followed
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5034fde05b55413fddf82f1869a9e05b
https://pubmed.ncbi.nlm.nih.gov/16076875
https://pubmed.ncbi.nlm.nih.gov/16076875
Autor:
Bradley W. Blaser, Darshna Bhatt, Jim J. Xiao, Charles F. Eisenbeis, Srinivas Vourganti, Sameek Roychowdhury, Michael A. Caligiuri, Jason Chou, Mark R. Parthun, Robert A. Baiocchi, Ching-Shih Chen, Michael R. Grever, Chang Shi Chen, Amy K. Ferketich, Kenneth K. Chan, Aharon G. Freud
Publikováno v:
Journal of the National Cancer Institute. 96(19)
BACKGROUND Immune-compromised individuals are at increased risk for developing aggressive Epstein-Barr virus (EBV)-associated lymphoproliferative disorders after primary EBV infection or for reactivation of a preexisting latent EBV infection. We eval
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::190a8160a0110b84ba76d7983efc8bd5
https://pubmed.ncbi.nlm.nih.gov/15467034
https://pubmed.ncbi.nlm.nih.gov/15467034
Autor:
Charles F, Eisenbeis, Andrew, Grainger, Beth, Fischer, Robert A, Baiocchi, Lester, Carrodeguas, Sameek, Roychowdhury, Lei, Chen, Amy L, Banks, Thomas, Davis, Donn, Young, Nicole, Kelbick, Julie, Stephens, John C, Byrd, Michael R, Grever, Michael A, Caligiuri, Pierluigi, Porcu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 10(18 Pt 1)
Cytokine-induced modulation of innate immunity is being explored to enhance the activity of monoclonal antibodies. Severe combined immunodeficient (SCID) mice engrafted with peripheral blood leukocytes (PBLs) from Epstein Barr virus-seropositive dono
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::991d3f7f2a40dc451efa7cfb174680cd
https://pubmed.ncbi.nlm.nih.gov/15447996
https://pubmed.ncbi.nlm.nih.gov/15447996